New hope for transplant patients: drug may tame chronic GVHD without steroids
NCT ID NCT04294641
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug ibrutinib as a first treatment for people newly diagnosed with moderate to severe chronic graft-versus-host disease (cGVHD), a condition where donor cells attack the recipient's body after a stem cell transplant. Ten adults took ibrutinib daily for up to 2 years to see if it could control the disease without using steroids. The goal was to measure how many patients had a complete or partial response at 6 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GVHD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
Washington University, School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists investigate skin immune cells to understand Graft-Versus-Host disease
- Promising drug for Post-Transplant blood issues falls short in early trial
- Can a video visit ease chronic GVHD suffering? small study says maybe
- Study withdrawn: extended access to fostamatinib for transplant patients never launched
- New immune therapy combo aims to tame chronic GVHD in Steroid-Resistant patients